Arvinas (ARVN) Amortization of Deferred Charges (2019 - 2026)
Arvinas (ARVN) recorded quarterly Amortization of Deferred Charges of $300000.0 in Q1 2026, up 50.0% quarter-over-quarter from $200000.0 in Q4 2025, and down 90.91% on a YoY basis from $3.3 million in Q1 2025.
Arvinas (ARVN) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Arvinas' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $300000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 90.91% year-over-year to $300000.0; the TTM figure through Mar 2026 stood at $1.3 million (down 82.67% YoY), while the FY2025 annual figure was $4.3 million, down 6.52% from the prior year.
- Amortization of Deferred Charges was $300000.0 for Q1 2026 at Arvinas, up from $200000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $3.3 million in Q1 2025 to a low of -$700000.0 in Q4 2023.
- Historically, Amortization of Deferred Charges has averaged $723529.4 across 5 years, with a median of $500000.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Amortization of Deferred Charges sank 240.0% in 2023, then soared 725.0% in 2025.
- A 5-year view of Amortization of Deferred Charges shows it stood at $500000.0 in 2022, then tumbled by 240.0% to -$700000.0 in 2023, then surged by 242.86% to $1.0 million in 2024, then plunged by 80.0% to $200000.0 in 2025, then jumped by 50.0% to $300000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $300000.0 (Q1 2026), $200000.0 (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | -700,000.00 |
| Dec 31, 2023 | -700,000.00 |